
    
      This study is an open, two-stage, phase I study to evaluate the safety, tolerability,
      pharmacokinetics and preliminary efficacy of AB011 injection in patients with
      CLDN18.2-positive advanced solid tumors. The study is composed of two stages: stage I is for
      dose escalation and stage II is for dose expansion.
    
  